Janet R. Wade

Amstelveen, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Covariate modeling in pharmacometrics: General points for consideration.

Covariate modeling in pharmacometrics: General points for consideration.

Journal: CPT: pharmacometrics & systems pharmacology

Published: August 18, 2023

Characterization of exposure-response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study.

Characterization of exposure-response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study.

Journal: Cancer chemotherapy and pharmacology

Published: July 14, 2022

Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients.

Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients.

Journal: Journal of clinical pharmacology

Published: April 08, 2021

Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors.

Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors.

Journal: Journal of pharmacokinetics and pharmacodynamics

Published: July 02, 2019

Changing Body Weight-Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma.

Changing Body Weight-Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma.

Journal: Clinical pharmacology and therapeutics

Published: May 23, 2019

Time-Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma.

Time-Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma.

Journal: CPT: pharmacometrics & systems pharmacology

Published: January 22, 2019

Extrapolation of a Brivaracetam Exposure-Response Model from Adults to Children with Focal Seizures.

Extrapolation of a Brivaracetam Exposure-Response Model from Adults to Children with Focal Seizures.

Journal: Clinical pharmacokinetics

Published: September 09, 2017

Evaluation of brivaracetam efficacy as monotherapy in adult patients with focal seizures.

Evaluation of brivaracetam efficacy as monotherapy in adult patients with focal seizures.

Journal: Epilepsy research

Published: May 04, 2017

Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years.

Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years.

Journal: European journal of clinical pharmacology

Published: January 25, 2017

Ovarian clear cell carcinoma recurrence presenting as subcutaneous nodules.

Ovarian clear cell carcinoma recurrence presenting as subcutaneous nodules.

Journal: European journal of gynaecological oncology

Published: August 01, 2016

Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures.

Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures.

Journal: Journal of clinical pharmacology

Published: February 17, 2016

Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group.

Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group.

Journal: Journal of pharmacokinetics and pharmacodynamics

Published: September 18, 2015

Showing 1-12 of 15

Last Updated: 09/26/2026